Between Worlds

Tim Fu, founder of Studio Tim Fu, is one of the world’s leading experts in leveraging AI in architecture and construction. Fu established his practice in 2023 after working at Zaha Hadid Architects, and now heads a diverse team of architects and technologists, creating innovative workflows and designs that embrace AI's transformative power in architectural practice. Most recently, he was chosen to be a collaborating artist with OpenAI's new Sora generative AI platform.

How will AI change jobs? There are a lot of theories, and as of yet, scant conclusive evidence. However, if you did have to pick a 'canary in a coal mine' to understand the impact of generative AI on the future of work, one place to start would be the global freelance workforce. To understand how  machine intelligence might be influencing how freelancers get things done, I spoke with Matt Barrie, CEO of Freelancer.com, one of the world's leading online job marketplaces.

We are familiar with the rise of AI generated art, but what impact will these emerging technologies having on more traditional forms of artistic expression? To explore that question, I spoke with Virginia Damtsa, a renowned curator of contemporary art, who has worked with everyone from Peter Gabriel to Ai Weiwei, Cornelia Parker, Olafur Eliasson, Annette Messager and others.

On a recent visit to Barcelona, I sat down with Marco Bertini, one of the world’s foremost experts on dynamic pricing. Bertini is a professor of marketing at Esade University and the author of the book, ‘The Ends Game: How Smart Companies Stop Selling Products and Start Delivering Value,’ which examines how technology and society stimulate accountability, prompting companies to profit from the outcomes they deliver rather than the offerings they bring to market.

Ben Waber is one of the world’s leading experts on people analytics and organizational culture. He is the founder of Humanyze and a professor at MIT. We caught up in Tokyo to discuss the future of work and the impact of large language models (LLMs) on productivity.

I sat down with Pierre-Yves Calloc'h, Chief Digital Officer at Pernod Ricard, to discuss the company's journey in embracing AI, algorithms and automation to drive marketing effectiveness, sales performance, and consumer engagement. Pernod Ricard, known for its extensive portfolio of brands such as Absolut Vodka, Jameson, and Ballantine's, has been at the forefront of leveraging AI to make data-driven decisions and personalize consumer experiences.

Byron Reese, an acclaimed author, futurist, and entrepreneur shares his insights on the concept of ‘Agora’, a superorganism formed by the collective interactions of human beings. Drawing parallels complex adaptive systems like beehives, Reese argues that just as individual bees come together to create an entirely new organism with emergent properties, humans too form a higher-order entity through their differentiated roles and interactions.

What are the new challenges that generative AI is creating for copyright law? In this episode, I speak with Matt Hervey, the head of AI law at Gowling, to explore the legal intricacies surrounding the creation of content and ideas by large language models. In our discussion, Matt sheds light on the complex landscape of AI ownership, highlighting the differences in legal frameworks across various jurisdictions, such as the UK, EU, and US.

Mikko Hyppönen is a renowned Finnish cybersecurity expert and the Chief Research Officer at WithSecure. In our discussion, we delved into the rapidly evolving landscape of cybersecurity threats, particularly focusing on the impact of artificial intelligence and large language models

Dave Johnson is Chief Data and Artificial Intelligence Officer at Moderna, where he is responsible for all enterprise data capabilities from data engineering, data integration, data science, and software engineering. Johnson holds a PhD in Information Physics and has over 15 years of experience in software engineering and data science. He has spent more than a decade working exclusively in enterprise pharma and biotech companies.